RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an
effective treatment for prostate cancer.
PURPOSE: Randomized phase III trial to compare treatment with or without adjuvant radiation
therapy in men with stage III prostate cancer who have had radical prostatectomy and
lymphadenectomy recently.

The patients are being asked to take part in this study because they had prostate cancer
that was treated surgically and it has been determined that they might have a greater risk
of their prostate cancer returning or their prostate cancer has already returned.
The purpose of this study is to see what effects, good and/or bad, image guided proton based
radiation therapy, and/or conventional radiation therapy and hormonal therapy (if
applicable), has on the patient's prostate c...

This study is being done to determine the highest safe dose of the combination of
temsirolimus and axitinib; to learn the side effects when these drugs are given together;
and to determine how the patient's disease responds to treatment.
The combination of the drugs temsirolimus and axitinib has not been studied before so it is
unknown whether this treatment will have any benefit in the patient's cancer.
Temsirolimus is commercially available and approved for treatment of som...

RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy
may fight prostate cancer by reducing the production of androgens. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. It is not yet known whether hormone therapy plus mitoxantrone and prednisone is more
effective than hormone therapy alone for prostate cancer.
PURPOSE: This randomized phase III trial is studying hormone therapy, m...

RATIONALE: Prostatectomy may be an effective treatment for prostate cancer that has not
responded to radiation therapy.
PURPOSE: This phase II trial is studying how well prostatectomy works in treating patients
with recurrent or persistent prostate cancer that has not responded to radiation therapy.

The purpose of this trial is to assess the effects of combined therapy with androgen
ablation and OGX-011 (an antisense to clusterin) given prior to radical prostatectomy on
pathologic complete response rates in men with localized prostate cancer and high risk
features.

RATIONALE: The use of lycopene, a substance found in tomatoes, may keep prostate cancer from
growing or coming back after surgery.
PURPOSE: This randomized phase II trial is studying different doses of lycopene to compare
how well they work in treating patients undergoing radical prostatectomy for prostate
cancer.

RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and
by blocking the enzymes necessary for tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who
have relapsed prostate cancer following radiation therapy or radical prostatectomy.

RATIONALE: Studying changes in thymus function in patients who have been undergoing androgen
blockade therapy for prostate cancer may help doctors learn more about how well patients
will respond to treatment, may help in planning cancer treatment, and may help the study of
cancer in the future.
PURPOSE: This clinical trial is studying the effect of androgen blockade therapy on thymus
function in older patients who have undergone radical prostatectomy for localized prostate
...

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy
using toremifene may fight prostate cancer by reducing the production of androgens.
PURPOSE: Randomized phase II trial to study the effectiveness of toremifene followed by
radical prostatectomy in treating patients who have stage I or stage II prostate cancer.

RATIONALE: Nerve-sparing radical prostatectomy with nerve grafting followed by standard
therapies for erectile dysfunction may be effective in helping patients with prostate cancer
improve sexual satisfaction and quality of life. It is not yet known whether erectile
dysfunction therapy and nerve-sparing prostatectomy are more effective with or without nerve
grafting.
PURPOSE: This randomized phase II trial is studying nerve grafting and standard therapy to
see how well t...

National multicentric prospective open study, comparing two current surgical methods:
laparoscopic way versus open retropubic way among patients requiring a radical prostatectomy
for a localised prostate cancer.

The purpose of this study is to find out what effects, good and bad, the combination of
docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer
before removal the prostate (prostatectomy).

RATIONALE: Watchful waiting until symptoms appear may be effective in patients with prostate
cancer. It is not yet known if watchful waiting is more effective than prostatectomy for
early prostate cancer.
PURPOSE: Randomized phase III trial to compare surgery with watchful waiting in men who have
stage I or stage II prostate cancer.

The purpose of this study is to conduct a Phase I clinical trial involving in situ RTVP-1
gene therapy for prostate cancer. We will conduct necessary safety evaluations on a new
adenovirus that contains the human genes for RTVP-1. This virus will then be evaluated for
safety in men with prostate cancer prior to radical prostatectomy. Based on the preclinical
data, we hope that this treatment will induce not only a local cytotoxic and antiangiogenic
effect but also, a systemic...

Our objective is to evaluate the clinical outcomes for the anatomic radical perineal
prostatectomy (RPP) for the surgical management of prostate cancer. We will report the
perioperative, oncologic, and functional outcomes in patients undergoing the radical
perineal prostatectomy at our institution.

Sometimes blood levels of prostatic specific antigen (PSA) will rise in men who have had
prostate surgery or received radiation therapy for localized prostate cancer. A low value
for the PSA is more desirable as is may indicate no tumor growth. Giving the hormone
therapy intermittently (in cycles of treatment and off treatment periods) appears to delay
the change of prostate cancer to a type of prostate cancer that resists hormone therapy. If
it does, the prostate cancer wil...

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as
flutamide and buserelin may stop the adrenal glands from producing androgens. OGX-011 may
help flutamide and buserelin kill more tumor cells by making tumor cells more sensitive to
the drugs. Giving flutamide and buserelin with OGX-011 before surgery may shrink the tumor
so it can be removed during surgery.
PURPOSE: Phase I trial to study the effectiveness of combining hormone therapy with OG...

This is a Phase I dose-escalation study of moderate dose radiation therapy prior to radical
prostatectomy for patients with high-risk localized disease. Its hypothesis is that such
treatment will be well tolerated with similar side effect profile as surgery alone.
Patients in Groups 1 and 2 will receive 39.6 Gy and 45 Gy (at 1.8 Gy/fx), respectively, to
the whole pelvis. Patients in Groups 3 and 4 will receive 45 Gy to the whole pelvis,
followed by a boost to the prostate and...